| ABCD2 | |
|---|---|
| Full Name | ATP Binding Cassette Subfamily D Member 2 |
| Chromosome | 12q12 |
| NCBI Gene ID | [225](https://www.ncbi.nlm.nih.gov/gene/225) |
| OMIM | [601081](https://www.omim.org/entry/601081) |
| Ensembl ID | ENSG00000173208 |
| UniProt ID | [Q9H0H5](https://www.uniprot.org/uniprot/Q9H0H5) |
| Associated Diseases | X-linked Adrenoleukodystrophy, Zellweger Spectrum, Alzheimer's Disease, Parkinson's Disease |
ABCD2 (ATP Binding Cassette Subfamily D Member 2) is a peroxisomal ATP-binding cassette transporter primarily involved in the import of very long-chain fatty acids (VLCFAs) and branched-chain fatty acids into peroxisomes for beta-oxidation[1]. As a member of the ALD subfamily (along with ABCD1 and ABCD3), ABCD2 plays a critical role in maintaining lipid homeostasis, particularly in the brain where peroxisomes are essential for myelin maintenance and neuronal function[2].
Research over the past decade has revealed that ABCD2 dysfunction extends beyond peroxisomal disorders like X-linked adrenoleukodystrophy (X-ALD) to encompass broader neurodegenerative mechanisms, including those involved in Alzheimer's disease and Parkinson's disease[@ito2020; @kou2021]. The gene is particularly important in oligodendrocytes, the myelin-producing cells of the central nervous system, where it supports the high metabolic demand of myelin lipid synthesis[3].
The ABCD2 gene is located on chromosome 12q12 and encodes a 706-amino acid peroxisomal membrane protein. Like other ABC subfamily D members, ABCD2 functions as a half-transporter that requires dimerization with partner molecules (typically ABCD1) to form a functional heterodimeric transporter[4].
The ABCD2 protein contains several key structural features:
The protein's topology places both the NBDs in the cytosol, where they interact with the ATPase subunits to drive conformational changes that transport substrates across the peroxisomal membrane[5].
ABCD2's primary function is the peroxisomal import of very long-chain fatty acids (VLCFAs, C24-C30)[2:1]:
ABCD2 has significant functional overlap with ABCD1:
Beyond VLCFA metabolism, ABCD2 participates in[@correia2017]:
ABCD2 exhibits tissue-specific expression with particular importance in neural tissues[2:2]:
While X-ALD is primarily caused by ABCD1 mutations, ABCD2 modifies disease severity[7]:
ABCD2 dysfunction contributes to AD pathogenesis through multiple mechanisms[@ito2020; @liu2022]:
VLCFA accumulation: Impaired peroxisomal import leads to VLCFA buildup in neuronal membranes, disrupting lipid raft composition and amyloid precursor protein (APP) processing[8]
Myelin breakdown: Oligodendrocyte dysfunction from ABCD2 deficiency causes white matter abnormalities visible on MRI in AD patients
Oxidative stress: Peroxisomal dysfunction reduces H2O2 scavenging capacity, increasing reactive oxygen species (ROS) that damage neurons[9]
Neuroinflammation: Peroxisome-deficient astrocytes release pro-inflammatory cytokines, promoting microglial activation and chronic neuroinflammation[6:1]
ABCD2 plays a role in PD through[@kou2021; @ruiz2023]:
Several therapeutic strategies targeting ABCD2 are under investigation[11]:
| Approach | Status | Mechanism |
|---|---|---|
| PPAR agonists | Preclinical | Upregulate ABCD2 expression |
| Gene therapy | Research | AAV-mediated ABCD2 delivery |
| Small molecule modulators | Research | Increase ABCD2 transporter activity |
| Cell therapy | Research | Transplant ABCD2-competent cells |
Berger et al. (2019): Established the link between peroxisomal ABC transporters and general neurodegenerative mechanisms[1:1]
Ito et al. (2020): Demonstrated peroxisomal dysfunction in Alzheimer's disease brains, with ABCD2 downregulation correlating with disease severity[12]
Kou et al. (2021): Showed that peroxisome deficiency in dopaminergic neurons recapitulates key features of Parkinson's disease pathology[13]
Weinhofer et al. (2022): Identified specific ABCD2 variants that modify disease severity in X-ALD patients[7:1]
Zhang et al. (2024): Discovered that ABCD2 deficiency disrupts lipid raft dynamics in neuronal membranes, affecting synaptic function[8:1]
Several mouse models have been developed to study ABCD2 function:
ABCD2 interacts with several key proteins and pathways[14]:
Berger J, et al. Peroxisomal ABC transporters in neurodegeneration. J Inherit Metab Dis. 2019. ↩︎ ↩︎
Ferrer I, et al. ABCD2 and peroxisomal VLCFA metabolism in the mouse brain. J Lipid Res. 2005. ↩︎ ↩︎ ↩︎
Sharer JD, et al. Very long-chain fatty acid metabolism in oligodendrocyte differentiation. J Neurochem. 2021. ↩︎
Kemp S, et al. ABCD2 as therapeutic target in X-linked adrenoleukodystrophy. Mol Ther. 2011. ↩︎ ↩︎ ↩︎
van Veldhoven PP, et al. Biochemistry and physiology of peroxisomal beta-oxidation. Biochim Biophys Acta Mol Cell Biol Lipids. 2019. ↩︎
Yamada T, et al. Peroxisome deficiency in microglia contributes to neuroinflammation. Glia. 2021. ↩︎ ↩︎
Weinhofer I, et al. ABCD2 variants modify disease severity in X-linked adrenoleukodystrophy. Brain. 2022. ↩︎ ↩︎
Zhang L, et al. ABCD2 and lipid raft dynamics in neuronal membranes. J Biol Chem. 2024. ↩︎ ↩︎
Pomatto V, et al. Oxidative stress and peroxisomal dysfunction in aging neurons. Redox Biol. 2023. ↩︎
Petranovic D, et al. Peroxisomal ABC transporters and fatty acid oxidation in aging brain. Aging Cell. 2019. ↩︎
Trotter C, et al. Peroxisome proliferator-activated receptor agonists and ABCD2 expression. Pharmacol Res. 2020. ↩︎
Ito Y, et al. Peroxisomal dysfunction and lipid metabolism alterations in Alzheimer's disease. J Alzheimers Dis. 2020. ↩︎
Kou J, et al. Peroxisome function in Parkinson's disease. Nat Rev Neurol. 2021. ↩︎
Marchetti DP, et al. Peroxisomes in brain development and function. Biochim Biophys Acta Mol Basis Dis. 2022. ↩︎